Drug Profile

ITF 3912

Alternative Names: ITF-3912; Peptide-drug conjugate - Italfarmaco

Latest Information Update: 08 Jul 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Italfarmaco
Class Antineoplastics; Peptide drug conjugates
Mechanism of Action DNA inhibitors; DNA synthesis inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Solid tumours

Most Recent Events

17 Apr 2026 Preclinical trials in Solid tumours in Italy (Parenteral)
17 Apr 2026 Pharmacodynamics data from a preclinical study in Solid tumours presented at the 117th Annual Meeting of the American Association for Cancer Research (AACR-2026)
14 Dec 2023 Italfarmaco in-licenses linker-payload technology from Nerviano Medical Sciences to develop peptide-drug conjugates for Cancer

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com